AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

Shernan G. Holtan, Luis F. Porrata, Ivana N M Micallef, Douglas J. Padley, David J. Inwards, Stephen A. Ansell, Patrick B. Johnston, Dennis A. Gastineau, Svetomir N. Markovic

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.

Original languageEnglish (US)
Pages (from-to)315-318
Number of pages4
JournalClinical Lymphoma and Myeloma
Volume7
Issue number4
DOIs
StatePublished - Jan 2007

Keywords

  • Autograft absolute lymphocyte count
  • Endpoint
  • Granulocyte colony-stimulating factor

Fingerprint Dive into the research topics of 'AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this